|
1. BIOLOGIE
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
A promising step forward for predicting lung cancer [Google]
|
|
|
|
|
|
These initial results are encouraging, but further studies will assess the impact and utility in clinical practice. We’re collaborating with Google Cloud Healthcare and Life Sciences team to serve this model through the Cloud Healthcare API and are in early conversations with partners around the world to continue additional clinical validation research and deployment.
|
|
|
|
|
|
|
|
|
Artificial intelligence diagnoses lung cancer [BBC News]
|
|
|
|
|
|
The results, in Nature Medicine, showed the AI could boost cancer detection by 5% while also cutting false-positives (people falsely diagnosed with cancer) by 11%. Dr Mozziyar Etemadi, from Northwestern University, told the BBC: "The next step is to use it on patients in the form of a clinical trial."
|
|
|
|
|
|
|
A.I. Took a Test to Detect Lung Cancer. It Got an A. [NY Times]
|
|
|
|
|
|
Asked if artificial intelligence would put radiologists out of business, Dr. Topol said, “Gosh, no!” The idea is to help doctors, not replace them. “It will make their lives easier,” he said. “Across the board, there’s a 30 percent rate of false negatives, things missed. It shouldn’t be hard to bring that number down.”
|
|
|
|
|
|
|
4.5 DÉP., DIAG. & PRONO. - COLORECTAL
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
UK charity sells Keytruda rights for $1.3B [Biopharma Dive]
|
|
|
|
|
|
For $1.3 billion, a pension plan run by the Canadian government has acquired royalty rights to Merck & Co.'s Keytruda from Lifearc, a charity responsible for handling intellectual property rights on discoveries made under the United Kingdom's Medical Research Council.
|
|
|
|
|
|
|
LifeArc monetises Keytruda® royalty interests to fund further research and investment [LifeArc]
|
|
|
|
|
|
LifeArc secured rights to royalties from pembrolizumab as a result of the charity’s 2007 collaboration to humanise the antibody-based therapy now marketed by MSD. The transaction will make LifeArc one of the UK’s leading medical research charities by size of its investment assets and allows it to significantly expand its mission of advancing research that has direct benefits for human health.
|
|
|
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|